Evidence map›Paper›PMID 32348495›Full record

ArticleThe Journal of infectious diseases2020

Interferon-Induced Transmembrane Protein 3 Genetic Variant rs12252-C Associated With Disease Severity in Coronavirus Disease 2019.

Yonghong Zhang, Ling Qin, Yan Zhao, Ping Zhang, Bin Xu, Kang Li, Lianchun Liang, Chi Zhang, Yanchao Dai, Yingmei Feng and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 109 papers, 10 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
109citing papers in PubMed, 10 pooled it
13.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

109 citing papers in PubMed, 10 syntheses or guidelines pooled it, 188 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Frontiers in genetics · 2022
    Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Trial
  12. Article
  13. mBio · 2025
    Review
  14. From defense to disease: IFITM3 in immunity and Alzheimer's disease.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2025
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article

49 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Yonghong ZhangBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Ling QinBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Yan ZhaoBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Ping ZhangChinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, United Kingdom.
Bin XuBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Kang LiBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Lianchun LiangBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Chi ZhangBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Yanchao DaiBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Yingmei FengBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Jianping SunBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Zhongjie HuBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Haiping XiangBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Julian C KnightChinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, United Kingdom.
Tao DongChinese Academy of Medical Science Oxford Institute, University of Oxford, Oxford, United Kingdom.
Ronghua JinBeijing Youan Hospital, Capital Medical University, Beijing, People's Republic of China.
Beijing YouAn Hospital · CNCapital Medical University · CNScience Oxford · GBUniversity of Oxford · GB

Funding

Medical Research Council MR/L018942/1Wellcome Trust 204969/Z/16/Z
6 · The paper itself

Abstract

A major unanswered question in the current global coronavirus disease 2019 (COVID-19) outbreak is why severe disease develops in a small minority of infected individuals. In the current article, we report that homozygosity for the C allele of rs12252 in the interferon-induced transmembrane protein 3 (IFITM3) gene is associated with more severe disease in an age-dependent manner. This supports a role for IFITM3 in disease pathogenesis and the opportunity for early targeted intervention in at-risk individuals.

Indexed as

AllelesPolymorphism, Single NucleotideSeverity of Illness IndexAdultAgedAged, 80 and overBetacoronavirusCohort StudiesCoronavirus InfectionsCOVID-19FemaleGenotypeHigh-Throughput Nucleotide SequencingHomozygoteHospitalizationHumansIFITM3 protein, humanMembrane ProteinsRNA-Binding ProteinsCOVID-19IFITM3rs12252severe pneumonia

Identifiers

PMID32348495
PMCPMC7197559
OpenAlexW3019343194

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.